Dysregulated expression of the EMX2OS/miR-34c-5p/TBL1XR1 regulatory axis: a novel signature for severe community-acquired pneumonia in children Authors: Yu Yan, Pengyi Wu, Dan Li, Xiao Zhou Published: 2026 ABSTRACT AbstractBackgroundMolecular pathology of severe community acquired pneumonia (SCAP) stays undefined; EMX2OS displays dysregulated expression in inflammation-related conditions, meriting exploration of its SCAP role. This study sought to investigate the expression pattern and clinical significance of EMX2OS in SCAP.MethodsSerum samples were collected from SCAP patients and healthy controls. RT-qPCR was employed to measure expression levels of EMX2OS, miR-34c-5p, and TBL1XR1 in serum and in LPS-stimulated BEAS-2B cells. Cell viability was assessed using CCK-8 assay, apoptosis was evaluated by flow cytometry, and inflammatory cytokines TNF-α, IL-1β, and IL-6 were quantified by ELISA. Oxidative stress and ferroptosis markers including MDA, GSH, and iron were determined using commercial kits. Molecular interactions were verified by dual-luciferase reporter assay and RNA immunoprecipitation.ResultsSerum EMX2OS and TBL1XR1 were upregulated whereas miR-34c-5p was downregulated in SCAP patients; EMX2OS demonstrated diagnostic utility and served as a risk factor. In LPS-stimulated BEAS-2B cells, EMX2OS and TBL1XR1 increased while miR-34c-5p decreased, accompanied by reduced viability, enhanced apoptosis, elevated inflammatory cytokines, and aberrant oxidative stress and ferroptosis markers, all of which were reversed by EMX2OS silencing. EMX2OS bound directly to and negatively regulated miR-34c-5p, which in turn bound directly to and suppressed TBL1XR1. Rescue experiments revealed that miR-34c-5p inhibition partially restored cellular injury phenotypes under EMX2OS silencing, and additional TBL1XR1 knockdown reversed these effects.ConclusionsOur findings suggest that EMX2OS is associated with inflammation, oxidative stress, and ferroptosis in SCAP, potentially by sponging miR-34c-5p to upregulate TBL1XR1.Keywords: EMX2OS, miR-34c-5p, TBL1XR1, Severe community acquired pneumonia, Ferroptosis Background Despite decades of advances in pediatric care, community-acquired pneumonia (CAP) remains a leading cause of pediatric mortality [1, 2]. When CAP progresses to its severe form (SCAP), clinicians face far greater challenges: patients deteriorate rapidly, complications such as acute respiratory distress syndrome become more likely, and survivors often contend with lasting health impairments [3, 4]. The molecular mechanisms driving pediatric SCAP remain poorly defined despite progress in antibiotics and supportive therapies, impeding early diagnostic and targeted therapeutic development, underscoring the need for further investigation into disease progression [5]. SCAP arises from a maladaptive immune reaction to diverse infectious agents, triggering a cascade of uncontrolled inflammatory signaling, heightened reactive oxygen species generation, and progressive alveolar damage [6]. This pathophysiological convergence, driven by both microbial factors and individual susceptibility, frequently progresses to acute respiratory distress syndrome [7] and ventilatory dependence, defining the critical illness spectrum. Unraveling these complex molecular underpinnings, including alterations in gene expression and cellular pathways, is paramount for identifying novel diagnostic avenues and developing more efficacious therapeutic strategies tailored for pediatric SCAP. Consequently, the discovery of robust early-warning indicators and druggable molecular entities represents a pressing research priority within pediatric critical care respiratory medicine [8, 9]. Long noncoding RNAs (lncRNAs), transcripts surpassing 200 nucleotides that lack protein-coding potential, have surfaced as pivotal modulators of transcriptional programs implicated across diverse disease contexts, pulmonary disorders included [10]. Within the realm of pediatric lower respiratory tract infections and associated inflammatory parenchymal lung diseases, accumulating evidence positions particular lncRNA species as critical orchestrators governing host defense mechanisms, inflammatory amplification circuits, and programmed cell death cascades. For example, the lncRNA DLEU2 has been shown to aggravate inflammatory injury and apoptosis in pediatric viral pneumonia via the miR-330-5p [11], while lncRNA MANCR promotes inflammation and suppresses cell viability in severe community-acquired pneumonia through the miR-20a-5p/MAPK1 pathway [12], and lncRNA GAS5 has been found to inhibit cell apoptosis and reduce inflammatory responses in childhood pneumonia by downregulating miR-155 [13]. Despite such progress, the biological functions of most lncRNAs remain largely undefined, and their specific implications in childhood SCAP warrant additional study. Among characterized lncRNAs, EMX2OS stands out for its dysregulated expression across malignancies and inflammatory disorders. A 2025 study reported marked EMX2OS elevation in neonatal sepsis, identifying it as a candidate diagnostic marker; mechanistically, this lncRNA drives ferroptosis in lung epithelial cells via the miR-654-3p/AKT3 axis, aggravating acute lung injury [14]. Whether EMX2OS operates through similar pathways, regulating airway epithelial damage, immune signaling, or ferroptosis, in pediatric pneumonia remains experimentally undefined. Methods Sample collection Sample size was determined using G*Power software for a two-sample t-test, with an effect size of 0.5, α of 0.05, and power of 0.8, yielding 64 participants per group; we ultimately enrolled 67 per group to account for potential dropouts. The study was conducted in accordance with the Declaration of Helsinki. Ethics approval was granted by Shounan Community Health Service’s Ethics Committee. Written informed consent was collected from all guardians. The length of hospital stays for SCAP patients ranged from 3 to 12 days. Serum was obtained from 67 pediatric pneumonia cases and 67 age-matched healthy controls. SCAP was defined by ≥ 1 major criterion (e.g., mechanical ventilation, shock) or ≥ 2 minor criteria (e.g., tachypnea, hypoxia, multilobar infiltrates) [4]. Children with SCAP were included as cases; those with immunodeficiency, congenital heart disease, or chronic lung disease were excluded. Blood samples were collected within 24 h of admission. Specimens were collected in sterile tubes, clotted at room temperature for 30 min, centrifuged at 3,000 rpm for 10 min, then aliquoted and frozen at − 80 °C. Clinical data, including age, gender, body mass index (BMI), and laboratory parameters such as white blood cell (WBC) count, lymphocyte (LYM) count, and neutrophil (NEU) count, were collected from the medical records of all participants. Bronchial epithelial cell culture and stimulation Cultured in DMEM (Gibco, USA) with 10% fetal bovine serum and 1% penicillin‑streptomycin (Beyotime, Shanghai, China), BEAS-2B cells (ATCC, USA) were maintained at 37 °C in a 5% CO2 humidified incubator. To mimic pneumonia in vitro, 1 µg/mL lipopolysaccharide (Sigma‑Aldrich, Darmstadt, Germany) was applied for 12 h [15]. Transfection procedures All transfection reagents were provided by GenePharma (Shanghai, China), including si‑lnc (EMX2OS‑targeting), oe‑lnc (EMX2OS overexpression), miR‑34c‑5p mimic/inhibitor, si‑TBL1XR1, and their respective negative controls. Cells seeded in six‑well plates at 70% confluency were transfected with Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) following the prescribed protocol. Medium was replaced with fresh complete medium after 6 h, and cells were harvested at 48 h post‑transfection. RT‑qPCR analysis RNA isolation from BEAS-2B cells and serum utilized TRIzol (Invitrogen, USA), with cDNA prepared using PrimeScript RT (TaKaRa, Japan). qPCR was performed on a QuantStudio 5 system (Applied Biosystems, USA) with SYBR Premix Ex Taq II (TaKaRa, Japan). Reference genes: GAPDH for TBL1XR1, β‑actin for SLC7A11 and GPX4, and U6 for EMX2OS and miR‑34c‑5p. Bioinformatics screening strategy Candidate lncRNA‑interacting miRNAs were identified using Starbase. MiRNAs irrelevant to disease or upregulated in patients were removed. Downstream targets of the selected miRNA were predicted via TargetscanHuman, miRDB, and GeneCards, with overlapping genes identified. The final target was selected by functional relevance and disease linkage. Luciferase reporter assay Predicted binding interactions included EMX2OS with miR‑34c‑5p (Starbase) and miR‑34c‑5p with TBL1XR1 (TargetScanHuman). For each target, wild-type reporter plasmids were constructed by inserting PCR-amplified fragments of the EMX2OS sequence or the TBL1XR1 3’UTR containing the predicted miR-34c-5p binding sites into the pmirGLO vector, while mutant plasmids were generated by introducing point mutations in the seed‑binding regions. Corresponding wild‑type and mutant reporter plasmids were generated by GenePharma (Shanghai, China). Transfected cells were lysed after 48 h for luciferase measurement using the Dual‑Luciferase system (Promega, Madison, WI, USA). Ago2‑based RIP RIP was conducted with the Magna RIP Kit (Millipore, USA). Lysates were incubated overnight at 4 °C with Ago2‑conjugated or control IgG beads. Precipitated RNA was analyzed for EMX2OS, miR‑34c‑5p, and TBL1XR1 enrichment. Cell counting Kit-8 (CCK-8) Following treatment, BEAS-2B cells cultured in 96‑well plates were incubated with 10 µL CCK‑8 solution (Dojindo, Japan) for 2 h at 37 °C. Absorbance at 450 nm was then recorded on a microplate reader (Bio‑Tek, USA). Flow cytometry Apoptosis was assessed via flow cytometry using Annexin V‑FITC/PI (Beyotime, Shanghai, China). Treated cells were stained for 15 min at room temperature in the dark and analyzed on a flow cytometer (BD Biosciences, USA). ELISA Concentrations of TNF‑α, IL‑1β, and IL‑6 in cell culture supernatants were quantified using ELISA kits (R&D Systems, Minneapolis, MN, USA). Absorbance was measured at 450 nm following the manufacturer’s protocol. Oxidative stress markers in BEAS‑2B cells Supernatants harvested from treated BEAS‑2B cells were assessed for malondialdehyde (MDA) and glutathione (GSH) using a Cell MDA assay kit and a Reduced GSH assay kit (Nanjing Jiancheng, China) in line with the manufacturers’ specifications. Iron assay Iron levels were determined using a commercial kit (Nanjing Jiancheng, China). Cell homogenates were centrifuged at 13,000 × g for 10 min at 4 °C, and the resulting supernatant was incubated with buffer for 10 min at 37 °C [14]. Statistical methods GraphPad Prism and SPSS served for data processing. Student’s t‑test was applied for two‑group comparisons, while one‑way ANOVA with Sidak’s correction was used for multiple groups. Correlations between molecules were examined by Pearson analysis. Diagnostic performance was assessed via ROC curves, and SCAP predictors were identified using binary logistic regression. The chi‑square test was employed for categorical baseline variables. Results EMX2OS is upregulated in SCAP and contributes to LPS‑induced cellular injury Clinical characteristics of the study participants are summarized in Table 1. SCAP patients and healthy controls were comparable in age, gender, and BMI, whereas WBC, LYM, and NEU counts were significantly higher in the SCAP group (Table 1). EMX2OS expression was higher in serum from SCAP patients than in healthy controls (Fig. 1A). ROC curve analysis indicated diagnostic value of EMX2OS for SCAP (AUC = 0.878, sensitivity 76.1%, specificity 88.1% at the optimal cut-off) (Fig. 1B). Logistic regression analysis identified EMX2OS as a risk factor for SCAP, with an odds ratio of 9.782 (p < 0.001), which was more significant than the associations observed for WBC count (OR: 3.400, p = 0.017) and LYM count (OR: 4.322, p = 0.004) (Table 2). Table 1Clinical information of the patients and controlsCharacteristicsControl (n = 67)SCAP (n = 67)p valueAge (years)5.79 ± 1.636.07 ± 1.620.314Gender (male/female)39/2842/250.596BMI (kg/m2)22.91 ± 2.0322.59 ± 2.380.397WBC (109/l)7.14 ± 1.519.16 ± 2.10<0.001***LYM (109/l)2.01 ± 0.362.66 ± 0.69<0.001***NEU (109/l)4.11 ± 0.865.62 ± 1.39<0.001***SCAP Severe community acquired pneumonia, BMI Body mass index, WBC White blood cells, LYM Lymphocytes, NEU NeutrophilsStatistical significance, ***p < 0.001 Clinical information of the patients and controls SCAP Severe community acquired pneumonia, BMI Body mass index, WBC White blood cells, LYM Lymphocytes, NEU Neutrophils Statistical significance, ***p < 0.001 EMX2OS is upregulated in SCAP patients and LPS-stimulated BEAS-2B cells, and its knockdown alleviates LPS-induced cellular injury. A EMX2OS expression in serum from healthy controls (n = 67) and SCAP patients (n = 67). B ROC curve evaluating the diagnostic value of EMX2OS for SCAP. C Transfection efficiency of EMX2OS overexpression and knockdown in BEAS-2B cells compared with respective negative controls. D-F Effects of EMX2OS silencing on cell viability (D), apoptosis (E), and inflammatory cytokine (IL-1β, TNF-α, and IL-6) levels (F) under LPS stimulation. LPS treatment induced significant cellular injury, which was attenuated by EMX2OS knockdown. Data are presented as mean ± SD from four independent experiments. *** p < 0.001 Table 2Logistics regression analysisPredictorOdds ratio (OR)95% confidence interval (95% CI)p valueLncRNA EMX2OS9.7823.513–27.237<0.001***Age (years)1.3140.466–3.7030.605Gender (male/female)1.7420.617–4.9190.295BMI (kg/m2)1.1670.436–3.1250.758WBC (109/l)3.4001.246–9.2730.017*LYM (109/l)4.3221.595–11.7090.004**NEU (109/l)2.5350.934–6.8860.068BMI Body mass index, WBC White blood cells, LYM Lymphocytes, NEU NeutrophilsStatistical significance, *p < 0.05, **p < 0.01, ***p < 0.001 Logistics regression analysis BMI Body mass index, WBC White blood cells, LYM Lymphocytes, NEU Neutrophils Statistical significance, *p < 0.05, **p < 0.01, ***p < 0.001 In BEAS-2B cells, LPS stimulation increased EMX2OS expression, which was effectively reduced by si‑lnc transfection and increased by oe‑lnc transfection (Fig. 1C). Compared with the control group, LPS treatment reduced cell viability, increased the apoptotic rate, and elevated the levels of IL‑1β, TNF‑α, and IL‑6; these LPS‑induced effects were reversed upon EMX2OS knockdown (Fig. 1D‑F). EMX2OS modulates oxidative stress and ferroptosis MDA level was markedly increased under LPS stimulation, and this change was reversed by EMX2OS knockdown (Fig. 2A). GSH level decreased following LPS treatment and was restored after EMX2OS knockdown (Fig. 2B). Iron level was higher in the LPS‑stimulated group than in the control group, and lower in the EMX2OS knockdown group than in the LPS + si‑NC group (Fig. 2C). mRNA expression of SLC7A11 and GPX4 was reduced after LPS induction and was increased by EMX2OS knockdown (Fig. 2D). EMX2OS modulates oxidative stress and ferroptosis. A-B Levels of MDA and GSH following EMX2OS knockdown under LPS stimulation. C Iron levels after EMX2OS silencing. D mRNA expression of ferroptosis-related markers SLC7A11 and GPX4. LPS stimulation increased MDA and iron levels, decreased GSH content, and downregulated SLC7A11 and GPX4 expression; these alterations were reversed by EMX2OS knockdown. Data are presented as mean ± SD from four independent experiments. *** p < 0.001 EMX2OS directly binds to and regulates miR‑34c‑5p Binding sequences between EMX2OS and miR‑34c‑5p were predicted using the Starbase database (Fig. 3A). Dual‑luciferase assay revealed that miR‑34c‑5p mimic reduced, while its inhibitor elevated, the luciferase activity of wild‑type EMX2OS reporter plasmid relative to corresponding negative controls; no significant changes were observed in the mutant plasmid group (Fig. 3B). RIP assay confirmed that enrichment of EMX2OS and miR‑34c‑5p was higher in the Ago2 antibody immunoprecipitate than in the IgG control group (Fig. 3C). In the LPS‑induced cellular model, miR‑34c‑5p expression decreased following EMX2OS overexpression and increased following EMX2OS knockdown (Fig. 3D). Serum miR‑34c‑5p levels were lower in SCAP patients than in healthy controls (Fig. 3E). MiR‑34c‑5p expression correlated negatively with EMX2OS expression (Fig. 3F). EMX2OS directly binds to and regulates miR-34c-5p. A Predicted binding sequences between EMX2OS and miR-34c-5p with mutations indicated. B Dual-luciferase reporter assay validating the interaction between EMX2OS and miR-34c-5p. C RIP assay confirming their direct binding via Ago2 enrichment. D MiR-34c-5p expression following EMX2OS overexpression or silencing under LPS stimulation. E MiR-34c-5p expression in serum from healthy controls and SCAP patients. F Pearson correlation analysis between miR-34c-5p and EMX2OS expression levels. Data are presented as mean ± SD from four independent experiments. ** p < 0.01, *** p < 0.001 MiR‑34c‑5p directly targets and regulates TBL1XR1 Overlapping analysis of multiple databases identified 5 potential target genes of miR-34c-5p (Fig. 4A). TBL1XR1 was selected as it correlates with childhood/infantile pneumonia via regulating inflammation, ferroptosis and NF-κB pathway [15, 16]. TargetScanHuman predicted a potential binding site between miR‑34c‑5p and TBL1XR1 (Fig. 4B). Dual‑luciferase assay showed that miR‑34c‑5p mimic decreased, while its inhibitor increased, wild‑type TBL1XR1 luciferase activity; no effect was observed in the mutant plasmid (Fig. 4C). RIP assay showed co‑enrichment of TBL1XR1 and miR‑34c‑5p in Ago2 complexes (Fig. 4D). LPS elevated TBL1XR1 expression, which was further enhanced by miR‑34c‑5p inhibition but repressed by its overexpression (Fig. 4E). Serum TBL1XR1 levels were higher in SCAP patients than in healthy controls (Fig. 4F) and correlated negatively with miR‑34c‑5p expression (Fig. 4G). MiR-34c-5p directly targets and regulates TBL1XR1. A Venn diagram showing overlapping target genes of miR-34c-5p from multiple databases. B Predicted binding sequences between miR-34c-5p and TBL1XR1 with mutations indicated. C Dual-luciferase reporter assay validating the interaction between miR-34c-5p and TBL1XR1. D RIP assay confirming their direct binding via Ago2 enrichment. E TBL1XR1 expression following miR-34c-5p inhibition or overexpression under LPS stimulation. F TBL1XR1 expression in serum from healthy controls and SCAP patients. G Pearson correlation analysis between TBL1XR1 and miR-34c-5p expression levels. Data are presented as mean ± SD from four independent experiments. *** p < 0.001 EMX2OS/miR‑34c‑5p/TBL1XR1 axis regulates cell viability, apoptosis, inflammation, oxidative stress, and ferroptosis Under LPS stimulation, relative to the condition of EMX2OS knockdown, additional inhibition of miR‑34c‑5p partially decreased cell viability, increased apoptosis, and elevated inflammatory cytokine levels (Fig. 5A‑D). These effects were attenuated by further knockdown of TBL1XR1. Similarly, compared to the same control, miR‑34c‑5p inhibition increased MDA and iron levels, decreased GSH levels, and downregulated the expression of SLC7A11 and GPX4; these effects were reversed by additional TBL1XR1 knockdown (Fig. 6A‑D). EMX2OS/miR-34c-5p/TBL1XR1 axis regulates cell viability, apoptosis, and inflammation. A Transfection efficiency of combined modulations with si-lnc, miR-34c-5p inhibitor, and si-TBL1XR1. B-D Effects of the EMX2OS/miR-34c-5p/TBL1XR1 axis on cell viability (B), apoptosis (C), and inflammatory cytokine levels (D) under LPS stimulation. EMX2OS silencing-induced protection was partially reversed by miR-34c-5p inhibition and subsequently rescued by additional TBL1XR1 knockdown. Data are presented as mean ± SD from four independent experiments. *** p < 0.001 EMX2OS/miR-34c-5p/TBL1XR1 axis modulates oxidative stress and ferroptosis. A-B Levels of MDA and GSH following combined modulation of EMX2OS, miR-34c-5p, and TBL1XR1. C Iron levels after combined interventions. D mRNA expression of ferroptosis-related markers SLC7A11 and GPX4. EMX2OS silencing-induced protection against ferroptosis was partially reversed by miR-34c-5p inhibition and subsequently restored by additional TBL1XR1 knockdown. Data are presented as mean ± SD from four independent experiments. *** p < 0.001 Discussion This study maps the EMX2OS/miR-34c-5p/TBL1XR1 axis in pediatric SCAP, interrogating its contributions to inflammation, oxidative injury, and ferroptotic cell death. We combined clinical specimen analysis with mechanistic work in BEAS-2B cells, a widely adopted bronchial epithelial model that recapitulates primary airway responses to bacterial triggers such as LPS, rendering it well-suited for dissecting pneumonia-associated epithelial damage [17, 18]. We first detected marked EMX2OS elevation in SCAP patient serum. ROC analysis confirmed its diagnostic strength (AUC = 0.878), while logistic regression singled out high EMX2OS as a SCAP risk predictor, outperforming both WBC and LYM counts. In vitro, LPS triggered EMX2OS induction in BEAS-2B cells; silencing this lncRNA markedly blunted LPS-driven cytotoxicity, apoptosis, and pro-inflammatory output. Prior research has identified EMX2OS as a regulatory lncRNA involved in various cancers [19, 20], and our findings extend its newly recognized role in inflammatory lung injury [14] specifically to pediatric SCAP while independently validating its diagnostic potential. A central finding of our investigation centers on EMX2OS-mediated regulation of oxidative stress and ferroptosis, an iron-dependent form of programmed cell death increasingly implicated in lung pathophysiology [21]. LPS treatment induced pronounced increases in MDA and intracellular iron levels, concomitant with a decrease in GSH and downregulation of ferroptosis suppressors SLC7A11 and GPX4. Strikingly, genetic knockdown of EMX2OS effectively rescued these molecular signatures of redox imbalance and ferroptotic priming. This regulatory nexus holds substantial pathobiological significance, given the expanding recognition that ferroptosis fuels alveolar epithelial demise and inflammatory propagation in acute lung injury models and infectious pneumonias [22, 23]. Our experimental findings suggest that EMX2OS may serve as a molecular accelerant of these deleterious cascades specifically within the SCAP disease context. Mechanistic exploration subsequently revealed a direct physical interaction between EMX2OS and miR-34c-5p. Dual-luciferase reporter systems coupled with RNA immunoprecipitation assays verified their specific molecular engagement, demonstrating that EMX2OS operates as a negative regulator of miR-34c-5p abundance. At the clinical level, miR-34c-5p displayed pronounced downregulation in SCAP patient serum, establishing a strong inverse relationship with EMX2OS expression profiles. These observations align with documented cytoprotective roles of miR-34c-5p across pulmonary disorders. Prior investigations have documented its significant depletion in chronic obstructive pulmonary disease, where experimental replenishment attenuates inflammatory burden [24]. Concordantly, its suppression has been detected in influenza A virus-infected A549 cells, implicating this microRNA in host antiviral machinery [25]. Collectively, our findings posit that EMX2OS functions as a competing endogenous RNA sequestering miR-34c-5p, thereby driving its pathological diminution in pediatric SCAP and undermining its salutary physiological functions. Moving downstream, we pinpointed TBL1XR1 as a bona fide target of miR-34c-5p. In silico predictions, substantiated by luciferase reporter and RIP assays, confirmed miR-34c-5p’s direct docking onto the TBL1XR1 3’UTR, establishing this microRNA as a negative modulator of TBL1XR1 expression. Concordantly, TBL1XR1 manifested significant upregulation in SCAP patient serum, mirroring an inverse trajectory with miR-34c-5p abundance. TBL1XR1 constitutes an integral subunit of the NCOR/SMRT transcriptional repression machinery, with established functions in immune surveillance, inflammatory transduction, and cellular fate determination [16, 26]. This multifunctional protein operates dually: as a transcriptional silencer orchestrating HDAC3-mediated deacetylation, and as a molecular switch catalyzing corepressor-coactivator exchange through ubiquitin-proteasome recruitment [27, 28], thereby exerting broad influence over diverse signaling networks. Rescue experiments ultimately confirmed the coordinated EMX2OS/miR-34c-5p/TBL1XR1 axis operation. EMX2OS silencing alleviated LPS-induced cellular injury, yet miR-34c-5p antagonism partially reversed these gains, impairing viability, restoring apoptosis, and reigniting inflammation. Crucially, TBL1XR1 knockdown rescued the phenotype, negating miR-34c-5p inhibition effects. This hierarchical crosstalk establishes EMX2OS as a central SCAP regulator, driving inflammation, oxidative damage, and ferroptosis via miR-34c-5p/TBL1XR1 control. Several limitations exist in this study. First, clinical data on pathogens, antibiotics, severity scores, and comorbidities were incomplete, leaving it unclear whether EMX2OS specifically marks SCAP severity or merely reflects systemic inflammation. Second, the cellular source of serum EMX2OS was not identified. Third, the absence of in vivo validation using animal models limits the generalizability of our conclusions. Future multi-center and animal studies are warranted to address these gaps. Conclusions In summary, this investigation identifies a novel EMX2OS/miR-34c-5p/TBL1XR1 regulatory axis operating in pediatric SCAP. We demonstrate that EMX2OS is clinically elevated and possesses diagnostic utility, and our in vitro findings suggest that it contributes to inflammation, oxidative stress, and ferroptosis by sponging miR-34c-5p, thereby permitting increased expression of TBL1XR1.